SMMT (Summit Therapeutics Inc.) Stock Financials & Earnings | Market Cap Arena

SMMT (Summit Therapeutics Inc.) Stock Financials & Earnings | Market Cap Arena

SMMTSummit Therapeutics Inc.

Mkt Cap$12B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$0

Net Income (TTM)-$1.1B

EPS (TTM)-$1.45

Free Cash Flow (TTM)-$324M

Gross Margin—

Op. Margin—

Net Margin—

FCF Margin—

P/S Ratio (TTM)—

P/E Ratio (TTM)—

YoY Rev Growth—

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$0	$0	-$537M
Q2 23	$235K	-$236K	-$16M
Q3 23	$0	-$599K	-$20M
Q4 23	$0	-$840K	-$28M
Q1 24	$0	-$27K	-$42M
Q2 24	$0	-$20K	-$60M
Q3 24	$0	-$20K	-$58M
Q4 24	$0	-$15M	-$66M
Q1 25	$0	-$25K	-$67M
Q2 25	$0	-$37K	-$568M
Q3 25	$0	-$42K	-$234M
Q4 25	$0	-$4K	$57M

Valuation

Quarter	P/S	P/E
Q1 23	26905.5x	—
Q2 23	26905.5x	—
Q3 23	52018.3x	—
Q4 23	52174.4x	—
Q1 24	52174.4x	—
Q2 24	—	—
Q3 24	—	—
Q4 24	—	—
Q1 25	—	—
Q2 25	—	—
Q3 25	—	—
Q4 25	—	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 23	-$13M	-$13M
Q2 23	-$29M	-$29M
Q3 23	-$15M	-$15M
Q4 23	-$19M	-$19M
Q1 24	-$30M	-$30M
Q2 24	-$33M	-$33M
Q3 24	-$30M	-$30M
Q4 24	-$49M	-$49M
Q1 25	-$61M	-$62M
Q2 25	-$67M	-$67M
Q3 25	-$95M	-$95M
Q4 25	-$100M	-$100M

Capital Expenditures

CapEx

Quarter	CapEx
Q1 23	$53K
Q2 23	$20K
Q3 23	$53K
Q4 23	$2K
Q1 24	$4K
Q2 24	$63K
Q3 24	$58K
Q4 24	$14K
Q1 25	$422K
Q2 25	$13K
Q3 25	$71K
Q4 25	$151K

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 23	-100.0%	+2297.2%
Q2 23	+0.0%	+24.0%
Q3 23	-100.0%	+19.4%
Q4 23	-100.0%	+39.9%
Q1 24	—	-92.1%
Q2 24	-100.0%	+271.9%
Q3 24	—	+183.6%
Q4 24	—	+131.0%
Q1 25	—	+57.7%
Q2 25	—	+853.5%
Q3 25	—	+303.0%
Q4 25	—	-187.3%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 23	$3M	—
Q2 23	$1M	628.3%
Q3 23	$578K	—
Q4 23	$7M	—
Q1 24	$8M	—
Q2 24	$11M	—
Q3 24	$19M	—
Q4 24	$11M	—
Q1 25	$11M	—
Q2 25	$479M	—
Q3 25	$0	—
Q4 25	$243M	—

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q1 23	$10M	$7M	—
Q2 23	$9M	$6M	—
Q3 23	$15M	$5M	—
Q4 23	$19M	$12M	—
Q1 24	$31M	$12M	—
Q2 24	$31M	$14M	—
Q3 24	$38M	$20M	—
Q4 24	$51M	$14M	—
Q1 25	$51M	$16M	—
Q2 25	$208M	$360M	—
Q3 25	$131M	—	$103M
Q4 25	$147M	$78M	—

Revenue Segments

Quarter

Revenue by Geography

Quarter

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$71M	$171M	$242M
Q2 23	$42M	$173M	$215M
Q3 23	$24M	$175M	$199M
Q4 23	$71M	$115M	$186M
Q1 24	$61M	$95M	$157M
Q2 24	$29M	$297M	$326M
Q3 24	$94M	$393M	$487M
Q4 24	$105M	$307M	$412M
Q1 25	$212M	$150M	$361M
Q2 25	$298M	$0	$298M
Q3 25	$239M	$0	$239M
Q4 25	$225M	$488M	$713M

Shares Outstanding

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q1 23	378M	+79.1%
Q2 23	698M	+84.5%
Q3 23	698M	+0.0%
Q4 23	702M	+0.6%
Q1 24	702M	+0.0%
Q2 24	708M	+0.9%
Q3 24	727M	+2.6%
Q4 24	738M	+1.5%
Q1 25	738M	+0.1%
Q2 25	743M	+0.6%
Q3 25	743M	+0.1%
Q4 25	748M	+0.6%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 20	$11K	79
FY 21	$17K	105
FY 22	$9K	76
FY 23	$0	105
FY 24	$0	159
FY 25	$0	200K